Dr. Bixiong Christopher Shue holds degrees from Beijing Medical University and Ohio University, where he completed his doctoral studies in the Department of Molecular and Cellular Biology and his post-doctoral training in the Edison Biotech Center.
In 1997, Dr. Shue joined the National Human Genome Research Institute (NHGRI) at the National Institute of Health (NIH) in Bethesda, Maryland as a research scientist. There, he focused on the study of genes involved in leukemia. Later, Dr. Shue joined Celera Genomics, in Rockville, Maryland as senior scientist and was involved in the sequencing and analysis of fruit fly, mouse, chimpanzee and human genetic codes.
In 2007, Dr. Shue took on a managerial role in the Shanghai RAAS Blood Product
Company in Shanghai, China, a US-Chinese joint venture. As a deputy manager in charge of R&D, he built up a team of talented researchers both from China and abroad.
In 2010, Dr. Shue became the president and CEO of the Shanghai Syndegen Biopharmaceutical Company, which focuses on the development of products based on protein factors and hormones with therapeutic value.
Dr. Shue has published numerous scientific articles.« back